

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Nissen SE, Tardif J-C, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. *N Engl J Med* 2007;356:1304-16.

## SUPPLEMENTAL APPENDIX

**Steering Committee:** **Dr. Steven E. Nissen MD**, Cleveland Clinic, OH (Chair and Principal Investigator); **Jean-Claude Tardif MD**, Montreal Heart Institute, Montreal, Canada (Associate Principal Investigator); **Philip J. Barter MBBS PhD**, The Heart Research Institute and Department of Medicine, University of Sydney, Australia; **H. Bryan Brewer Jr. MD**, Medstar Research Institute-Washington Hospital Center, Washington, DC; **Sidney C. Smith MD**, University of North Carolina, Chapel Hill, NC

**Clinical Events Adjudication Committee:** **Blair O'Neil, MD** (Chair) Chief of Service, Cardiology, Queen Elizabeth II Health Sciences Center Halifax, Nova Scotia; **Chris O'Connor MD**, Duke University Medical Center, Durham, NC 27710, **Udo Sechtem MD**, Robert Bosch Krankenhaus, Stuttgart, Germany, **Jean-Marc LaBlanche MD**, Hôpital Cardiologique, Lille, France; **Francine Welty MD**, Beth Israel/Deaconess, Boston, MA ; **J. Donald Easton MD**, Brown University, Providence, RI, **Martin M. Brown, MD**, University College London, United Kingdom.

**Intravascular Ultrasound Core Laboratory:** Tim Crowe, William Magyar, Aaron Loyd, Anne Colagiovanni, Tammy Churchill, Teresa Fonk, Jordan Andrews, Kara McInturff, Rhiannon Regal, Jay Zhitnik, Andrea Winkhart, Karilane King, Jessica Fox, Troy Schweitzer, Paula Shalling

### **In addition to the authors, the following investigators participated in this study:**

Instytut Kardiologii, Warszawa, Poland, **W. Ruzyllo**; Kaiser Foundation Hospital, San Francisco, CA, USA, **C. Goard**; Altos Cardiovascular Associates, Los Altos, CA, USA, **D. Curatola**; Orlando Heart Center, Orlando, FL, USA, **M. Steiner**; Cleveland Cardiovascular Research Foundation, Cleveland, OH, USA, **E. Nukta**; Broward Heart Specialists, Inc., Ft. Lauderdale, FL, USA, **V. Atanasoski McCormack**; LeBauer Cardiovascular Research Foundation, Greensboro, NC, USA, **B. Brodie**; Michigan Cardiovascular Institute, Saginaw, MI, USA, **R. Gudipati**; Cardiac & Vascular Research Center of Northern Michigan, Petoskey, MI, USA, **L. Cannon**; University of Virginia Health System, Charlottesville, VA, USA, **M. Ragosta**; Unidad de Hemodinámica, Servicio de Cardiología, Madrid, Spain, **F. Alfonso**; Peninsula Cardiology Associates, Salisbury, MD, USA, **F. Arena**; Śląska Akademia Medyczna w Katowicach, Katowice, Poland, **A. Ochala**; Ciutat Sanitària Vall d'Hebrón, Barcelona, Spain, **J. Angel**; Metropolitan Cardiology Consultants, Minneapolis, MN, USA, **J. Chambers**; Midwest Medical Group, LLC, South Bend, IN, USA, **D. Westerhausen**; Szpital Uniwersytecki w Krakowie, II Klinika Kardiologii, Krakow, Poland, **D. Dudek**; Upstate Cardiology, PA, Greenville, SC, USA, **J. Cebe**; University of Connecticut Health Center, Farmington, CT, USA, **M. Azrin**; Southwest Cardiology Associates, Inc. , Oklahoma City, OK , USA, **M. Yasin**; St. Mary's Duluth Clinic Health System, Duluth, MN, USA, **A. Chiu**; Central Minnesota Heart Center at St. Cloud Hospital, St. Cloud, MN, USA, **B. Erickson**; Borgess Research Institute/Borgess Medical Center, Kalamazoo, MI, USA, **T. Fischell**; Pennsylvania State University, The Milton S. Hershey Medical Center, Hershey, PA, USA, **I. Gilchrist**; VA Puget Sound Health Care System, Seattle, WA, USA, **K. Lehmann**; Seattle Cardiovascular Research, Bellevue, WA, USA, **T. Amidon**; Medical College of Ohio, Toledo, OH, USA, **W. Colyer**; Hospital Universitario Central de Asturias, Oviedo, Spain, **C. Moris**; St. Paul Heart Clinic, St. Paul, MN, USA, **K.**

**Baran**; Cardiology Consultantst , Pensacola, FL, USA, **W. Pickens**; The Heart and Vascular Institution of Florida, Safety Harbor, FL, USA, **R. Sharma**; Boulder Medical Center, Boulder, CO, USA, **M. Holland**; Hospital Universitario de Bellvitge, Barcelona, Spain, **A. Cequier Fillat**; Radiant Research - Santa Rosa , Santa Rosa, CA, USA, **S. Halpern**; Endovascular Research, LLC , Eugene, OR, USA, **S. Cook** ; Genesis Medical Center, Davenport, IA, USA, **E. Dippel**; HPV Heart, PA, Columbia, MD, USA, **W. Herzog**; San Diego VA Medical Center , San Diego, CA, USA, **W. Penny**; Buffalo Cardiology and Pulmonary Associates, PC, Williamsville, NY, USA, **J. Corbelli**; Cardiovascular Clinics, PC , Merrillvile, IN, USA, **T. Nguyen**; Centre Hospitalier de l'Université de Montréal, Montréal, QC, CAN, **F. Reeves** ; Foothills Medical Centre, Calgary, AB, CAN, **M. Traboulsi**; Miami International Cardiology Consultants, Miami, FL, USA, **J. Margolis**; Florida Cardiovascular Research at JFK Medical Center, Atlantis, FL, USA, **M. Rothenberg**; Cardiology Consultants, Norfolk, VA, USA, **D. Stine**; Parkway Cardiology Associates, Oak Ridge, TN, USA, **M. Sharma**; Oklahoma Heart Institute, Tulsa Ok , USA, **W. Leimbach**; Hospital General Universitario Gregorio Marañón, Madrid, Spain, **J. Elizaga**; Hospital del Mar, Barcelona, Spain, **A. Serra**; MetroHealth Medical Center, Heart and Vascular Center, Cleveland, OH, USA, ; Louisiana Medical Unversity, New Orleans, LA, USA, **S. Jain**; New Mexico Heart Institute, PA, Albuquerque, NM, USA, **J. Batty**; Southwest General Health Center, Middleburg Heights, OH, USA, **M. Schrode**; Hillsboro Cardiology, PC3, Hillsboro, OR, USA, **S. Promisloff**; University of Louisville, University Cardiology - Research Office, Louisville , KY, USA, **M. Leesar**; University of Pittsburgh Medical Center , Pittsburgh, PA, USA, **W. Anderson**; Cardiology Group of Western New York PC, Williamsville, NY, USA, **S. Calandra**; Corporate Woods, Albany, NY, USA, **A. Delago**; Wake Heart Research, Raleigh, NC, USA, **J. Mann**; University of Colorado Health Sciences Center, Denver, CO, USA, **J. Messenger**; VA Hospital, Memphis, TN, USA, **R. Ramanathan**; UCL - St Luc University Hospital, Cardiovascular Department, Bruxelles, Belgium, **J. Renkin**; Sunnybrook and Women's College Health Sciences Centre, Toronto, ON, CAN, **E. Cohen**; University of Ottawa Heart Institute3, Ottawa, ON, CAN, **M. Le May**; Queen Elizabeth II Health Sciences Center, Halifax, NS, CAN, **L. Title**; Northern California Medical Associates , Santa Rosa, CA, USA **D. Hopkins**; Baptist Hospital of East Tennessee, Knoxville, TN, USA, **M. Foster**; Doylestown Hospital Doylestown, PA, USA, **J. McGarvey**; Erasmus MC, Rotterdam, Netherlands, **P. Serruys**; Memphis Heart Clinic, Southaven MS, USA, **S. Himmelstein**; Milwaukee Cardiovascular Research Foundation, Milwaukee, WI, USA, **A. Arnold**; United Health Services Hospitals, Incorporated, Johnson City, NY, USA, **H. Kashou**; Inova Fairfax Hospital, Institute of Research, Falls Church, VA, USA, **B. Raybuck**; Michigan Heart, PC, Ypsilanti, MI, USA, **J. Wilks**; Mercy Heart Institute Research, Sacramento, CA, USA, **M. Chang**; The Heart Group, Lancaster, PA, USA, **R. Gentzler**; Hospital de Meixoeiro vigo, Pontevedra, Spain, **M. Sanmartin Fernandez**; Victoria Heart Institute Foundation, Victoria, BC, CAN, **J. Hilton**; UMC St. Radboud, Dept of Cardiology, Nijmegen, Netherlands, **W. Aengevaeren**; Sinai Hospital of Baltimore, Baltimore, MD, USA, **P. Gurbel**; William Beaumont Hospital, Royal Oak, MI, USA, **S. Dixon**; New York University Medical Center, New York, NY, USA, **M. Attubato**; Iowa Heart Center, P.C., Des Moines, IA, USA, **M. Ghali** ; Hospital of the University of Pennsylvania, Philadelphia, PA, USA, **H. Hermann**; Clearwater Cardiovascular and Interventional Consultants, Clearwater, FL, USA, **F. Lenz**; Rochester Cardiopulmonary Group, Rochester, NY, USA, **T. Stuver**; Yale University, New Haven, CT, USA, **S. Pfau**; Mobile Heart Specialists, PC, Mobile, AL, USA, **C. Brown**; Sacramento Heart & Vascular Research, Sacramento, CA, USA, **D. Roberts**; Hopital Sacré-Coeur de Montréal,

Montréal, QC, CAN, **E. Schampaert** ; Metropolitan Cardiology Associates, Pamona, NY, USA, **C. Hirsch** ; Cleveland Clinic, Cleveland, OH, USA, **R. Raymond** ; The Chattanooga Heart Institute, Chattanooga, TN, USA, **V. Monroe**; University of Arkansas for Medical Sciences, Little Rock, AR, USA, **L. Garza**; Forsyth Medical Center, Winston-Salem, NC, USA, **W. Means**; Shawnee Mission, Shawnee, Mission, KS, USA, **S. Rowe**; Buffalo Heart Group, Buffalo, NY, USA, **A. Masud**; Los Angeles Cardiology Associates, Los Angeles, CA, USA, **R. Matthews**; Arkansas Heart Hospital, Little Rock, AR, USA, **D. Mego**; University Hospital of Cleveland, Cleveland, OH, USA, **R. Nair**; McGuire Research Institute, Inc., Richmond, VA, USA, **A. Minisi**; The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, **S. Bailey**; Hudson Valley Heart Center, Poughkeepsie, NY, USA, **M. Jaffar** ; Hopital Maisonneuve-Rosemont, Montréal, QC, CAN, **C. Constance** ; Wake Forest University Health Services, Winston-Salem, NC, USA, **T. Baki**; University of Minnesota, Cardiovascular Division, Minneapolis, MN, USA, **A. Berger**; University of Washington Medical Center, Seattle, WA, USA, **S. Goldberg**; Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO, USA, **S. Marso**; University of Alabama at Birmingham, Birmingham, AL, USA, **V. Misra**; University of Michigan Health Systems, Ann Arbor, MI, USA, **S. Chetcuti**; Kaiser Permanente of Colorado, Denver, CO, USA, **S. Resnick**; Nebraska Health System, University of Nebraska Medical Center, Omaha, NE, USA, **S. Shurmur**; University Cardiovascular Services, Huntington, WV, USA, **M. Studney**; Washington Adventist Hospital, Takoma Park, MD, USA, **M. Turco**; New York Hospital Queens, Flushing , NY, USA, **S. Papadakos**; Saint Joseph's Medical Center, Stockton, CA, USA, **D. Primack**; Saint Agnes Medical Center, Fresno, CA, USA, **D. Merrill**; Rockford Cardiology Associates, Rockford, IL, USA, **R. Minor**; Ziekenhuis Oost-Limburg, Genk, Belgium, **M. Vrolix**; East Carolina; University School of Medicine, Greenville, NC, USA, **J. Babb**; South Bay Cardiovascular, West Islip, NY, USA, **D. Reich**; Androscoggin Cardiology Associates, Auburn, ME, USA, **R. Weiss**; University of Rochester Medical Center, Rochester, NY, USA, **C. Cove**; Cardiology Institute of Michigan , Lapeer, MI, USA, **J. Harris**; University of Pennsylvania Medical Center – Presbyterian Philadelphia, PA, USA, **R. Li**; Volunteer Research Group, LLC, Knoxville, TN, USA, **D. Wortham**; Melbourne Internal Medicine Associates, Melbourne, FL, USA, **R. Vicari**; Diagnostic Cardiology Associates , Jacksonville, FL, USA, **G. Pilcher**; Miami Cardiology Group, Miami, FL, USA, **J. Roberts**; Onze-Lieve-Vrouw Hospital, Aalst, Belgium, **M. Vanderheyden**; University of Arkansas for Medical Sciences, Little Rock, AR, USA, **Y. Aude**; University of Florida Health Science Center Jacksonville, Jacksonville, FL, USA, **P. Gilmore**; Heart Care Research Foundation , Marrisonette Park, IL, USA, **R. Iaffaldano**; Kansas City Cardiology Associates, Kansas City, MO, USA, **E. Hockstad**

**Supplemental Table**

**Primary Efficacy Parameter (Percent Atheroma Volume) in Pre-specified Subgroups**

<b>Characteristic at Baseline (n-monotherapy; n-torcetrapib)</b>	<b>Atorvastatin Monotherapy LS Mean (SE)</b>	<b>Atorvastatin- Torcetrapib LS Mean (SE)</b>	<b>Difference LS mean (SE)</b>	<b>95% CI on Difference LS mean</b>	<b>P value†</b>
Age < 65 (n=331; 359)	0.15 (0.16)	0.06 (0.15)	-0.09 (0.22)	(-0.51, 0.33)	0.68
Age ≥ 65 (n=115; 105)	0.29 (0.28)	0.38 (0.29)	0.09 (0.40)	(-0.71, 0.88)	
Male (n=319; 331)	0.17 (0.16)	0.11 (0.16)	-0.06 (0.23)	(-0.51, 0.38)	0.89
Female (n=127; 133)	0.20 (0.24)	0.19 (0.24)	-0.01 (0.34)	(-0.68, 0.67)	
HDL-C < 40 mg/dL (n=150; 167)	0.24 (0.24)	0.32 (0.32)	0.08 (0.33)	(-0.56, 0.73)	0.89
HDL-C ≥ 40 mg/dL (n=292; 288)	0.18 (0.17)	0.07 (0.17)	-0.11 (0.24)	(-0.58, 0.36)	
LDL-C < median (n=217; 241)	0.01 (0.20)	0.08 (0.19)	0.06 (0.27)	(-0.47, 0.59)	0.64
LDL-C ≥ median (n=225; 214)	0.39 (0.19)	0.26 (0.19)	-0.13 (0.27)	(-0.66, 0.40)	
Triglycerides < 150 mg/dL (n=294, 286)	-0.01 (0.17)	-0.17 (0.17)	-0.16 (0.24)	(-0.63, 0.30)	0.78
Triglycerides ≥ 150 mg/dL (n=149; 169)	0.60 (0.23)	0.71 (0.21)	0.11 (0.31)	(-0.51, 0.73)	
Current smoker (n=71; 75)	0.42 (0.35)	0.44 (0.34)	0.02 (0.49)	(-0.95, 0.98)	0.97
Non-smoker or former smoker (n=375; 389)	0.14 (0.15)	0.06 (0.14)	-0.08 (0.21)	(-0.49, 0.32)	
History of Diabetes (n=94; 87)	0.76 (0.31)	0.77 (0.32)	0.01 (0.45)	(-0.88, 0.90)	0.82
No History of Diabetes (n=352; 377)	0.03 (0.15)	-0.02 (0.14)	-0.05 (0.21)	(-0.46, 0.36)	
History of Hypertension (n=336; 345)	0.19 (0.16)	0.11 (0.15)	-0.08 (0.22)	(-0.51, 0.35)	0.94
No History of Hypertension (n=110; 119)	0.19 (0.27)	0.15 (0.26)	-0.03 (0.37)	(-0.76, 0.70)	
Metabolic Syndrome (n=192;194)	0.32 (0.21)	0.42 (0.21)	0.11 (0.30)	(-0.47, 0.69)	0.89
No Metabolic Syndrome (n=254; 270)	0.05 (0.18)	-0.05 (0.17)	-0.11 (0.25)	(-0.59, 0.38)	
CRP at baseline <3.0 mg/L (n=293; 293)	0.00 (0.17)	0.13 (0.17)	0.13 (0.24)	(-0.34, 0.60)	0.16
CRP at baseline ≥3.0 mg/L (n=141; 163)	0.60 (0.24)	0.20 (0.22)	-0.40 (0.32)	(-1.04, 0.24)	
PAV < median (n=225; 230)	0.21 (0.17)	0.61 (0.17)	0.40 (0.24)	(-0.06, 0.87)	0.005
PAV ≥ median (n=221; 234)	0.19 (0.21)	-0.37 (0.21)	-0.57 (0.30)	(-1.15, 0.01)	

† p value for subgroup interaction

LS=Least squares

SE=Standard error

CRP=High Sensitivity C-reactive Protein

LDL-C = Low Density Lipoprotein Cholesterol

HDL-C = High Density Lipoprotein Cholesterol

PAV = percent atheroma volume